SAHA Patient: IV vs ORAL (200 mg/dose)



FIG. 1

Protocol 01-021 (ORAL SAHA) ARM A: SOLID TUMOR PATIENTS Cohort I (200 mg/dose)



FIG. 2

SAHA Patients: ORAL /Coh rt I (200 mg/dose)



FIG. 3

Protocol 01-021 (ORAL SAHA)
ARM A: SOLID TUMOR PATIENTS
Cohort I (200 mg/dose)



FIG. 4


Protocol 01-021 (ORAL SAHA)
ARM A: SOLID TUMOR PATIENTS
Cohort IIa (400 mg/dose)
7-OS-400
8-OS-400
IV
ORAL
IV
ORAL
-
+
Markers
Pre
Post
Pre
15 min
2 hr
6 hr
Pre
Post
Pre
0 hr
2 hr
α–AcH3
Coomassie stain
12/19/01


9-OS-400
IV
ORAL
-
+
Markers
Pre
Post
Pre
2 hr
6 hr
α–AcH3
Coomassie stain
12/27/01

FIG. 5

SAHA Patients: ORAL/Cohort II (400 mg/dose)



FIG. 6


Pr tocol 01-021 (ORAL SAHA)
ARM A: SOLID TUMOR PATIENTS
Cohort IIa (400 mg/dose)
ORAL
ORAL
- + M
Pre IV
2 hrs IV
Pre D 1
2 hrs D 1
Pre D21
2 hrs D 21
8 hrs D 21
α–AcH3
8-OS-400 (01/18/02)
Coomassie stain
ORAL
ORAL
- + M
Pre IV
2 hrs IV
Pre D 1
2 hrs D 1
6 hrs D 1
Pre D21
2 hrs D 21
9 hrs D 21
α–AcH3
9-OS-400 (01/18/02)
Coomassie stain
ORAL
ORAL
- + M
Pre IV
2 hrs IV
Pre D 1
2 hrs D 1
8 hrs D 1
Pre D21
2 hrs D 21
10 hrs D 21
α–AcH3
10-OS-400 (01/24/02)
Coomassie stain

FIG. 7

SAHA Patients· ORAL/Cohort II (400 mg/dose)





FIG. 8

Oral 200 mg vs. 400 mg (Fasting)



Figure 9A

Oral 200 mg vs. 400 mg (no-fasting)



Figure 9B

IV 200 mg vs. 400 mg



Figure 9C

Apparent Half-life of the Oral Dose



■=200 mg group (n=3-5); □=400 mg group (n=5-10)

3/4/2003

Figure 10

AUC of the Oral Dose



■ =200 mg group (n=3-5); □ =400 mg group (n=5-10)

3/4/2003

Figure 11

Bioavailability



Figure 12

MESOTHELIOMA



PRE

POST

Figure 13